Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xianjun Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9758-7079; OpenAlex author ID A5100736390. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 3 papers · 2025: 3 papers

Papers 8

  1. Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ygeno.2025.111048↗
  2. Tumor Volume Evaluation is a Superior Predictor of Prognosis Compared to RECIST in Metastatic Pancreatic Ductal Adenocarcinoma Undergoing Immunochemotherapy Co-author DOI 10.21203/rs.3.rs-7634457/v1↗
  3. The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.7150/thno.111180↗
  4. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  5. NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy. Co-author DOI 10.1038/s41419-024-06984-0↗
  6. NLRP4 drives olaparib resistance in pancreatic cancer. First author DOI 10.1080/27694127.2024.2422729↗
  7. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Last author DOI 10.1038/s41388-020-01452-3↗
  8. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Co-author DOI 10.1186/s12943-019-1117-9↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Si Shi · 5 shared papers, 2019–2025 · strength 1.22
  2. Mingming Xiao · 3 shared papers, 2024–2025 · strength 0.85
  3. Xuhui Tong · 2 shared papers, 2024–2025 · strength 0.49
  4. Jing Yang · 1 shared paper, 2025 · strength 0.28
  5. Wei Wang · 1 shared paper, 2025 · strength 0.28
  6. Dingxia Liu · 1 shared paper, 2025 · strength 0.27
  7. Yajia Gu · 1 shared paper, 2025 · strength 0.27
  8. Miaoyan Wei · 1 shared paper, 2025 · strength 0.27
  9. Qinglin Fei · 1 shared paper, 2025 · strength 0.24
  10. Weiding Wu · 1 shared paper, 2025 · strength 0.24
  11. Long‐Yun Ye · 1 shared paper, 2025 · strength 0.24
  12. Kaizhou Jin · 1 shared paper, 2025 · strength 0.24
  13. Xiaoqi Mao · 1 shared paper, 2024 · strength 0.21
  14. Mingwei Dong · 1 shared paper, 2024 · strength 0.21
  15. Yalan Lei · 1 shared paper, 2024 · strength 0.21
  16. H. J. Yang · 1 shared paper, 2024 · strength 0.21
  17. Yosuke Inoue · 1 shared paper, 2024 · strength 0.16
  18. Satoshi Nara · 1 shared paper, 2024 · strength 0.16
  19. Naohiro Okano · 1 shared paper, 2024 · strength 0.16
  20. Shinichiro Takahashi · 1 shared paper, 2024 · strength 0.16
  21. Hiroki Yamaue · 1 shared paper, 2024 · strength 0.16
  22. Tomohisa Yamamoto · 1 shared paper, 2024 · strength 0.16
  23. Junji Furuse · 1 shared paper, 2024 · strength 0.16
  24. Kazuhiro Yoshida · 1 shared paper, 2024 · strength 0.16
  25. Yukiyasu Okamura · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.